Authors

Eric Winer, MD, is the director of Yale Cancer Center, as well as president and physician-in-chief at Smilow Cancer Hospital.

Latest:

Dr Winer on Considerations for Inavolisib Plus Palbociclib and Fulvestrant in PIK3CA-Mutated HR+/HER2– Breast Cancer

Eric Winer, MD, discusses considerations for inavolisib plus palbociclib with fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative breast cancer.

Alberto Martini, MD

Alberto Martini, MD, is

Latest:

Dr Martini on the Mechanism of Action of Cretostimogene Grenadenorepvec in Urothelial Carcinoma

Alberto Martini, MD, discusses cretostimogene grenadenorepvec in urothelial carcinoma.

Samer Al Hadidi

Latest:

Getting the Best From Mentorship

Mentors may help in career development, personal matters, research activities, and professional growth.

Aaron Franke, MD

Latest:

Dr Franke on Treatment Options for NSCLC Expressing Uncommon EGFR Mutations

Aaron J. Franke, MD, MS, discusses treatment options for patients with uncommon EGFR mutations in non–small cell lung cancer.

Marta Vaz Batista, MD

Latest:

Dr Vaz Batista on Treating Patients With HER2+ Breast Cancer and Leptomeningeal Carcinomatosis

Marta Vaz Batista, MD, discusses the efficacy of trastuzumab deruxtecan in patients with HER2-positive or HER2-low advanced breast cancer and pathologically confirmed leptomeningeal carcinomatosis, as evaluated in cohort 5 of the phase 2 DEBBRAH study.

Rachel Elizabeth Rau, MD

Latest:

Blinatumomab Plus Chemo in Newly Diagnosed, Standard-Risk Pediatric B-ALL

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss data for blinatumomab plus chemotherapy in newly diagnosed pediatric ALL.

İlker Arslan, MD

Latest:

Camidge and Arslan Calculate the “Impact Factor” of a Career in Medicine

Drs Camidge and Arslan discuss Dr Arslan’s experience providing emergency medical care and the curiosity that led him to pursue a career in industry.

Juan Javier-Desloges, MD, MS

Latest:

Frontline Therapeutic Planning for Metastatic Renal Cell Carcinoma

In this review, authors highlight multidisciplinary treatment for patients with advanced disease, and integrating systemic therapy options with surgery and radiation therapy.

Azka Ali, MD

Azka Ali, MD, is a medical oncologist in the Department Hematology and Medical Oncology at the Cleveland Clinic Taussig Cancer Institute.

Latest:

Dr Ali on the Need to Refine Predictive Strategies for Endocrine Sensitivity in HER2-Low Breast Cancer

Azka Ali, MD, discusses the need to refine predictive strategies for endocrine sensitivity in HER2-low metastatic breast cancer.

Soo Park, MD

Latest:

Selecting Candidates for Adjuvant Immunotherapy in cSCC

Panelists discuss how clinicians identify which patients are most likely to benefit from adjuvant immunotherapy based on clinical and pathologic risk factors.

Giuseppe Giaccone, MD, PhD

Latest:

Dr. Giaconne on the Lack of Funding for Rare Cancers Research

Giuseppe Giaccone, MD, PhD, highlights the difficulties with funding for research focused on rare cancers.

Coral Olazagasti, MD

Latest:

Navigating Novel IO Regimens and ADCs in Lung Cancer With Drs Rodriguez, Olazagasti, and Roy

Estelamari Rodriguez, MD, MPH, Coral Olazagasti, MD, and Tina Roy, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Amy DeZern, MD, MHS

Latest:

Closing Thoughts on the MDS Treatment Landscape

Following its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.

Kevin Punie, MD, PhD

Kevin Punie, MD, PhD, is a medical oncologist working as a staff member at the department of General Medical Oncology in the University Hospitals Leuven.

Latest:

Dr Punie on Patient-Reported Outcomes With Sacituzumab Govitecan vs Chemotherapy in Advanced TNBC

Kevin Punie, MD, discusses PRO data from the phase 3 ASCENT-03 trial.

Polly Niravath, MD

Latest:

Dr Niravath on Durvalumab, Trastuzumab, and Pertuzumab in HER2-Enriched Breast Cancer

Polly Niravath, MD, discusses a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab in HER2-enriched early breast cancer.

Timothy Gershon, MD, PhD

Latest:

Dr Gershon on Ongoing Research Priorities for NF1-Associated Plexiform Neurofibromas

Timothy R. Gershon, MD, PhD, discusses ongoing research priorities neurofibromatosis type 1–associated plexiform neurofibromas

Ranjit S. Bindra, MD, PhD

Latest:

Dr Bindra on the Role of MGMT Loss on Resistance Mechanisms in Cancer

Ranjit S. Bindra, MD, PhD, discusses a new class of DNA modifiers which selectively target tumor DNA with the goal of overcoming resistance mechanisms across multiple types of cancer.

Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center

Latest:

Sequencing Later-Line Therapies for Metastatic Urothelial Carcinoma

A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.

Howard M. Ross, MD

Latest:

Dr. Ross on the Role of the Microbiome in CRC

Howard M. Ross, MD, discusses the role of the microbiome colorectal cancer.

Mili Arora, MD

Latest:

In the Trenches With the Fellows

Mili Arora, MD, talks about changing the fellowship program at UC Davis, the effect the COVID-19 pandemic has had on her trainees, and the importance of working late nights with her fellows.